Open Access Open Badges Research article

Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma

Eliana Bignotti1*, Laura Zanotti1, Stefano Calza23, Marcella Falchetti4, Silvia Lonardi4, Antonella Ravaggi1, Chiara Romani1, Paola Todeschini1, Elisabetta Bandiera1, Renata A Tassi1, Fabio Facchetti4, Enrico Sartori1, Sergio Pecorelli1, Dana M Roque5 and Alessandro D Santin5

Author Affiliations

1 “Angelo Nocivelli” Institute of Molecular Medicine, Division of Gynecologic Oncology, University of Brescia, Viale Europa 11, 25123, Brescia, Italy

2 Department of Biomedical Sciences and Biotechnology, Section of Medical Statistics and Biometry, University of Brescia, Viale Europa 11, 25123, Brescia, Italy

3 Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, SE-17177, Stockholm, Sweden

4 Department of Pathology, University of Brescia, Viale Europa 11, 25123, Brescia, Italy

5 Department of Obstetrics, Gynecology & Reproductive Sciences, Yale University School of Medicine, 333 Cedar Street, PO Box 208063, New Haven, CT 06520-8063, USA

For all author emails, please log on.

BMC Clinical Pathology 2012, 12:22  doi:10.1186/1472-6890-12-22

Published: 14 November 2012



Endometrial cancer is the most common gynecologic malignancy in developed countries. Trop-2 is a glycoprotein involved in cellular signal transduction and is differentially overexpressed relative to normal tissue in a variety of human adenocarcinomas, including endometrioid endometrial carcinomas (EEC). Trop-2 overexpression has been proposed as a marker for biologically aggressive tumor phenotypes.


Trop-2 protein expression was quantified using tissue microarrays consisting of formalin-fixed paraffin-embedded specimens from 118 patients who underwent surgical staging from 2001–9 by laparotomy for EEC. Clinicopathologic characteristics including age, stage, grade, lymphovascular space invasion, and medical comorbidities were correlated with immunostaining score. Univariate and multivariate analyses were performed for overall survival, disease-free survival, and progression-free survival in relation to clinical parameters and Trop-2 protein expression.


Clinical outcome data were available for 103 patients. Strong Trop-2 immunostaining was significantly associated with higher tumor grade (p=0.02) and cervical involvement (p<0.01). Univariate analyses showed a significant association with reduced disease-free survival (DFS) (p=0.01), and a trend towards significance for overall and progression-free survival (p=0.06 and p=0.05, respectively). Multivariate analyses revealed Trop-2 overexpression and advanced FIGO stage to be independent prognostic factors for poor DFS (p=0.04 and p <0.001, respectively).


Trop-2 protein overexpression is significantly associated with higher tumor grade and serves as an independent prognostic factor for DFS in endometrioid endometrial cancer.

Endometrioid endometrial cancer; Trop-2; TACSTD2; Tissue microarrays; Prognostic factor